CD47 Targeting Therapeutics Market is expected to grow at a 35% CAGR during the forecast period for 2028-2034.
Key Industry Insights & Findings from the Report:
CD47 is immunoglobulin and supramolecular complex composed of integrins, G protein, and cholesterol. It mediates a series of processes such as cell proliferation, migration, phagocytosis, apoptosis, immune homeostasis, and inhibition of NO signalling. In recent years, CD47 also called the “don’t eat me” signal, has been highly expressed on the surface of various cancers, initiating an inhibitory signalling pathway that prevents cancer cells from phagocytosis by macrophages.
The factors driving the growth of the CD47 targeting therapeutics market include the rising developments in the CD47-targeting anti-cancer therapies, growing demand for cost-efficient cancer treatments, increasing government initiatives for cancer awareness, and R&D initiatives by market players for launching effective cancer therapies, and the growing number of cancer cases worldwide. According to the NCI (National Cancer Institute), cancer is among the leading causes of death worldwide. By 2040, more cancer cases are expected to rise to 29.5 million per year and cancer-related deaths to 16.4 million. Recently, the American FDA has granted orphan drug designation ("ODD") to ALX Oncology's next-generation CD47 blocker ‘evorpacept’ for treating patients with gastroesophageal junction cancer and gastric cancer. Thus, the increasing prevalence of cancer is projected to surge the demand for advanced cancer therapies to treat cancer patients effectively, which will likely fuel the market growth over the forecast period. However, the high R&D cost of target therapies and side effects associated with these therapies are expected to hamper the market’s growth in the coming years.
The CD47 targeting therapeutics market is classified based on target disease indication, type of molecule, and region. The target disease indication, segment the market into acute myeloid leukemia, non-hodgkin lymphoma, colorectal cancer, diffuse large B-cell lymphoma, myelodysplastic syndromes, non-small cell lung cancers, ovarian epithelial cancer, oral mucositis, small cell lung cancers, and other disease indications. The acute myeloid leukaemia segment is anticipated to proliferate over the forecast period owing to the increased CD47 expression on human AML. The market is grouped into biologics and small molecules by type of molecule. Due to its increasing therapeutic applications, the biologics segment is expected to witness significant growth during the forecast years. Regionally, the market is considered across North America, Europe, Asia-Pacific, Latin America, the Middle East and Africa.
North America is likely to witness the highest growth during the forecast period due to the high prevalence of cancer, growing demand for CD47 therapeutic products, and the increasing approvals for immunoglobulins.
| Report Attribute | Specifications |
| Growth rate CAGR | CAGR of 35% from 2028 to 2034 |
| Quantitative units | Representation of revenue in US$ Million and CAGR from 2028 to 2034 |
| Historic Year | 2021 to 2024 |
| Forecast Year | 2028-2034 |
| Report Coverage | The forecast of revenue, the position of the company, the competitive market structure, growth prospects, and trends |
| Segments covered | By Target disease Indication, By Type of Molecule |
| Regional scope | North America; Europe; Asia Pacific; Latin America; Middle East & Africa |
| Country scope | U.S.; Canada; U.K.; Germany; China; India; Japan; Brazil; Mexico ;The UK; France; Italy; Spain; South Korea; South East Asia |
| Competitive Landscape | Conjupro biotherapeutics (US), EpicentRx (US), Forty Seven (US), ImmuneOncia Therapeutics (Korea), ImmuneOnco Biopharmaceuticals (China), Innovent Biologics (China), KAHR Medical (Israel), Light Chain Bioscience (Switzerland), Morphiex (US), Trillium Therapeutics (Canada), TG Therapeutics, Adagene, Alector, Inc., Apmonia Therapeutics, I-MAB Biopharma Co., Ltd., QLSF Biotherapeutics Inc., Phanes Therapeutics, Inc., Bio-Thera Solutions, others. |
| Customization scope | Free customization report with the procurement of the report, Modifications to the regional and segment scope. Particular Geographic competitive landscape. |
| Pricing and available payment methods | Explore pricing alternatives that are customized to your particular study requirements. |
Global CD47 Targeting Therapeutics Market, by Target Disease Indication, 2022-2030 (Value US$ Mn)
Global CD47 Targeting Therapeutics Market, by Type of Molecule, 2022-2030 (Value US$ Mn)
Global CD47 Targeting Therapeutics Market, by Region, 2022-2030 (Value US$ Mn)
North America CD47 Targeting Therapeutics Market, by Country, 2022-2030 (Value US$ Mn)
Europe CD47 Targeting Therapeutics Market, by Country, 2022-2030 (Value US$ Mn)
Asia Pacific CD47 Targeting Therapeutics Market, by Country, 2022-2030 (Value US$ Mn)
Latin America CD47 Targeting Therapeutics Market, by Country, 2022-2030 (Value US$ Mn)
Middle East & Africa CD47 Targeting Therapeutics Market, by Country, 2022-2030 (Value US$ Mn)
Competitive Landscape
Other Prominent Players
This study employed a multi-step, mixed-method research approach that integrates:
This approach ensures a balanced and validated understanding of both macro- and micro-level market factors influencing the market.
Secondary research for this study involved the collection, review, and analysis of publicly available and paid data sources to build the initial fact base, understand historical market behaviour, identify data gaps, and refine the hypotheses for primary research.
Secondary data for the market study was gathered from multiple credible sources, including:
These sources were used to compile historical data, market volumes/prices, industry trends, technological developments, and competitive insights.
Primary research was conducted to validate secondary data, understand real-time market dynamics, capture price points and adoption trends, and verify the assumptions used in the market modelling.
Primary interviews for this study involved:
Interviews were conducted via:
Primary insights were incorporated into demand modelling, pricing analysis, technology evaluation, and market share estimation.
All collected data were processed and normalized to ensure consistency and comparability across regions and time frames.
The data validation process included:
This ensured that the dataset used for modelling was clean, robust, and reliable.
The bottom-up approach involved aggregating segment-level data, such as:
This method was primarily used when detailed micro-level market data were available.
The top-down approach used macro-level indicators:
This approach was used for segments where granular data were limited or inconsistent.
To ensure accuracy, a triangulated hybrid model was used. This included:
This multi-angle validation yielded the final market size.
Market forecasts were developed using a combination of time-series modelling, adoption curve analysis, and driver-based forecasting tools.
Given inherent uncertainties, three scenarios were constructed:
Sensitivity testing was conducted on key variables, including pricing, demand elasticity, and regional adoption.